ADC

198개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved198 programs
ADCLimited DatastaleSanofi Pasteur, a Sanofi CompanyPhase 3

Meningococcal Polysaccharide (Meningococcal Polysaccharide, Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, serogroups A, C, Y, and W)

Meningococcal Infection (Healthy Volunteers) · Meningococcal Infection (Healthy Volunte

#MeningococcalInfectionHealthyVol#ADC#Phase3#antibody-drug-conjugate#Sanofi
Trials 1Status Active
ADCLimited DatastaleAbbViePhase 1

Mirvetuximab + SL-172154 (Mirvetuximab + SL-172154)

Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase1#antibody-drug-conjugate#FallopianTubeCancer+1
Trials 1Status Active
ADCLimited DatastaleMethylGene Inc.Phase 2

brentuximab vedotin (Adcetris, Mocetinostat Plus Brentuximab Vedotin)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#antibody-drug-conjugate#MethylGene
Trials 1Status Active
ADCLimited DatastaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+1
Trials 1Status Recruiting
ADCLimited DatastaleGilead SciencesPreclinical

ADC (Non-Investigational Antibody-Drug Conjugates, Non-Investigational Antibody-Drug Conjugates (ADC))

HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma · HER2

#HER2#ADC#Preclinical#antibody-drug-conjugate#HER2-negativeBreastCancer+2
Trials 1Status Recruiting
ADCLimited DatastaleOxford BioTherapeutics LtdPhase 1

OBT076, a CD205-directed antibody-drug conjugate (OBT076, a CD205-directed antibody-drug conjugate)

Solid Tumor · CD20

#CD20#ADC#Phase1#antibody-drug-conjugate#SolidTumor+1
Trials 1Status Recruiting
ADCLimited DatastaleBioAtla, Inc.Phase 2

Ozuriftamab Vedotin (Ozuriftamab Vedotin)

Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck · Head and Neck Cancer

#HeadandNeckCancer#ADC#Phase2#antibody-drug-conjugate#SquamousCellCarcinomaofHeadandNe+1
Trials 1Status Active
ADCLimited DatastaleMerckPhase 2

PEV (Pembrolizumab & Enfortumab Vedotin, Pembrolizumab & Enfortumab Vedotin (PEV))

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#ADC#Phase2#antibody-drug-conjugate#Merck
Trials 1Status Recruiting
ADCLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab + Enfortumab Vedotin)

Bellini Carcinoma; Collecting Duct Carcinoma · Bellini Carcinoma

#BelliniCarcinoma#ADC#Phase2#antibody-drug-conjugate#CollectingDuctCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase I: Glembatumumab Vedotin (Phase I: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase II: Glembatumumab Vedotin (Phase II: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleRochePhase 2

Polatuzumab vedotin, Glofitamab (Polatuzumab vedotin, Glofitamab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 1Status Recruiting
ADCLimited DatastaleRochePhase 2

Polatuzumab, bendamustin und rituximab (Polatuzumab, bendamustin und rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 1Status Recruiting
ADCLimited DatastaleSecond Affiliated Hospital, Zhe…Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48-ADC plus Bevacizumab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#ADC#Phase2#antibody-drug-conjugate#Second
Trials 1Status Active
ADCLimited DatastaleGileadPhase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan)

Metastatic Breast Cancer ( HER2 Negative) · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MetastaticBreastCancerHER2Negati+1
Trials 1Status Recruiting
ADCLimited DatastaleFudan UniversityPhase 2

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

Bladder Cancer; Metastatic Urothelial Carcinoma · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#MetastaticUrothelialCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleSichuan Kelun-Biotech Biopharma…Phase 2

SKB264 (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (SKB264))

Advanced Biliary Tract Cancer(BTC) · Advanced Biliary Tract Cancer(BTC)

#AdvancedBiliaryTractCancerBTC#ADC#Phase2#antibody-drug-conjugate#Sichuan
Trials 1Status Recruiting
ADCLimited DatastaleThe First Affiliated Hospital o…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Combined with Bevacizumab)

Platinum-resistant Recurrent Ovarian Cancer (PROC) · Platinum-resistant Recurrent Ovarian Can

#Platinum-resistantRecurrentOvari#ADC#Phase2#antibody-drug-conjugate#The
Trials 1Status Recruiting
ADCLimited DatastaleBiying ChenPhase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor)

Recurrent or Metastatic Head and Neck Carcinoma · MET

#MET#ADC#Phase2#antibody-drug-conjugate#RecurrentorMetastaticHeadandNeck+1
Trials 1Status Recruiting
ADCLimited DatastaleLi-kun ChenPhase 2

sacituzumab govitecan (Trodelvy, Sac-TMT, Sacituzumab tirumotecan, Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#Li-kun
Trials 1Status Recruiting

9 / 10 pages

← PreviousNext →